Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study

Abstract Objective We sought to determine if there is an association between fibroblast growth factor 21 (FGF21) levels and a history of gestational diabetes mellitus (GDM) in women with and without metabolic dysfunction, defined as a diagnosis of metabolic syndrome or type 2 diabetes (T2DM), 5 to 10 years following participation in a multiple cohort GDM study. Study Design At 5 to 10 years after index pregnancy, women underwent a follow-up visit and were categorized as having no metabolic syndrome, metabolic syndrome, or T2DM. FGF21 levels were compared between women who did and did not have a history of GDM using multivariable linear regression. Results Among 1,889 women, 950 underwent follow-up and 796 had plasma samples analyzed (413 GDM and 383 non-GDM). Total 30.7% of women had been diagnosed with T2DM or metabolic syndrome. Overall, there was no difference in median FGF21 levels in pg/mL between the prior GDM and non-GDM groups (p = 0.12), and the lack of association was observed across all three metabolic categories at follow-up (p for interaction = 0.70). Conclusion There was no association between FGF21 levels and prior history of mild GDM in women with and without metabolic dysfunction 5 to 10 years after the index pregnancy (ClinicalTrials.gov number, NCT00069576, original trial).

Download Full-text

Relationship between fibroblast growth factor 21 and thyroid stimulating hormone in healthy subjects without components of metabolic syndrome

Family Medicine and Community Health ◽

10.15212/fmch.2014.0118 ◽

2014 ◽

Vol 2 (3) ◽

pp. 1-6

Author(s):

Tianxu Fu ◽

Shanshan Yuan ◽

Ying Gao ◽

Chenxue Qu ◽

Lan Chen ◽

...

Keyword(s):

Metabolic Syndrome ◽

Growth Factor ◽

Fibroblast Growth Factor ◽

Healthy Subjects ◽

Thyroid Stimulating Hormone ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth ◽

Stimulating Hormone

Download Full-text

Evaluation of Total Adiponectin, Adipocyte Fatty Acid Binding Protein and Fibroblast Growth Factor 21 Levels in Individuals With Metabolic Syndrome

Physiological Research ◽

10.33549/physiolres.932602 ◽

2014 ◽

pp. 219-228 ◽

Cited By ~ 9

Author(s):

D. NOVOTNY ◽

H. VAVERKOVA ◽

D. KARASEK ◽

J. LUKES ◽

L. SLAVIK ◽

...

Keyword(s):

Metabolic Syndrome ◽

Fatty Acid ◽

Growth Factor ◽

Fibroblast Growth Factor ◽

Fatty Acid Binding Protein ◽

Binding Protein ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth ◽

Fatty Acid Binding ◽

Acid Binding Protein

Although many studies have investigated the relationships of several adipokines to metabolic syndrome (MetS), the interrelationships of adiponectin (ADP), adipocyte fatty acid binding protein (A-FABP) and fibroblast growth factor 21 (FGF 21) have not been described in detail. We examined 209 asymptomatic dyslipidemic patients divided into MetS+ (n=73) and MetS- (n=136) groups. The aim of study was to evaluate the relationships between observed adipokines, to compare the levels of total ADP, A-FABP and FGF 21 in individuals with and without MetS, and to elucidate the relationships of individual adipokines to lipid parameters, markers of insulin resistance and endothelial hemostatic markers in these groups. In MetS+ group, we found the independent positive association ADP with A-FABP (beta=0.4888, p=0.0382), A-FABP with FGF 21 (beta=0.3811, p=0.0002) and von Willebrand factor (beta=0.4502, p=0.0013), and FGF 21 with A-FABP (beta=0.4422, p=0.0002). Our study has confirmed the well-established risk profile of subjects with MetS, although clinically asymptomatic. MetS+ patients had also lower levels of ADP and higher levels of A-FABP and FGF 21. Our study evaluated the interrelationships of ADP, A-FABP and FGF 21 in asymptomatic dyslipidemic subjects with diagnosis of MetS. Especially strong association between A-FABP and FGF 21 needs to be clarified in further studies.

Download Full-text